

Risperidone formulations: cost-effective switch in adults

Please note that this document has not been updated for the 2026-27 incentive scheme. Standard Operating Procedures (SOPs) for medicines optimisation switches/reviews, along with other supporting materials, were originally developed for use by Medicines Optimisation Team staff within NHS South Yorkshire Integrated Care Board (ICB). Other organisations or groups choosing to use this resource does so at their own risk and NHS SY ICB accepts no liability for its use or application.

1. Identify prescribing of risperidone orodispersible tablets for adults and gain agreement to switch to equivalent dose of liquid formulation. Consider if any barriers for handling liquid formulations. Communicate change with patients/ carers (see letter below)

Risperidone orodispersible 500mcg tablets x 28 - £18.28

Risperidone orodispersible 1mg tablets x 28 - £26.37

Risperidone orodispersible 2mg tablets x 28 - £38.14

Risperidone orodispersible 3mg tablets x 28 - £46.88

Risperidone orodispersible 4mg tablets x 28 - £53.94

Risperidone 1mg/ml oral solution sugar-free 100ml - £2.90*

Please note:

*Patients/carers are kindly asked to carry forward the stock instead of ordering every month unless any specific shelf-life advice by the manufacturer.

2. For any long -term prescribing (longer than 6 weeks) with no evidence of risperidone drug review identified for patients with dementia; you may wish to highlight it for prescriber led review for current appropriateness.

Refer to SPC/BNF/SCP for details.

[Antipsychotic-Prescribing-Toolkit-for-Dementia.pdf \(england.nhs.uk\)](https://www.england.nhs.uk/medicines/antipsychotic-prescribing-toolkit-for-dementia/)

3. Complete MAR chart for any patients living in a care home (see below)

Letter– generic/brand switch or brand to brand switch

PRACTICE ADDRESS

LIST OF GPs ETC

Private and Confidential

PATIENT NAME

NHS Number:

PATIENT ADDRESS

PATIENT ADDRESS

DATE

Dear

Your doctor has agreed a change to your prescription medication.

Prescribing at the practice is regularly reviewed to make sure patients are receiving the most suitable and cost- effective medication.

At the moment you take **Risperidone orodispersible tablets [strength] - [dose]**

This has been changed to **Risperidone 1mg/ml oral solution - [dose]**

The oral solution contains the same medication so work in the same way and is equally effective to orodispersible tablets, but the solution is available at a lower cost to the NHS. This means that the savings made by prescribing this instead of orodispersible tablets can then be used to support and improve other NHS services.

Please note:

- The change will not affect the way your condition is managed; you will continue to be monitored by your doctor as before.
- Your next repeat prescription will be changed to Risperidone 1mg/ml oral solution [dose]. Please continue to use your current supply of Risperidone orodispersible tablets [dose] as prescribed by your doctor until the pack is finished.
- The new Risperidone 1mg/ml oral solution should be used in exactly the same way as your old brand of medication. Do not use both together.
- Please read the patient information leaflet provided with the new medication.
- Upon opening the bottle, follow any shelf- life advice if this is stated by the manufacturer.
- This letter only refers to the change to Risperidone 1mg/ml oral solution. All your other medication should be taken as prescribed by your GP.

I hope you are happy about the reasons for this change. If you have any concerns or notice any changes in your condition, please contact the surgery.

Yours sincerely,

XXXXXXXXXX

Pharmacy Technician / Clinical Practice Pharmacist

Practice logo

Care home name

Your doctor has agreed a change to your resident's prescription medication

Resident name	D.O.B	Current prescribed item / dose/formulation / strength	Changed to	State if this is; 1) Medication changed to brand 2) Medication changed to generic 3) Cost effective alternative 4) Any other reason e.g. out of stock	Any precautionary message

The change will not affect the way the condition is managed and will continue to be monitored by the doctor as before

Please inform your dispensing pharmacy of the change in order to remove the original item from the MAR chart to prevent duplication

Additional message

--